Navigation Links
Dirucotide Does Not Meet Primary Endpoint in Phase III MAESTRO-01 Trial in Secondary Progressive Multiple Sclerosis
Date:7/27/2009

s, difficulty walking and paralysis(iii, iv).

MS is thought to affect as many as 2.5 million people worldwide, including approximately 400,000 in the United States(v). It is a disease that affects more women than men, with onset typically occurring between 20 and 50 years of age(v).

Approximately 30-40 percent of all MS patients have the secondary progressive form of the disease(vi), in which irreversible disability accumulates more steadily, with or without relapses(vii). There are few treatment options available for these patients(viii).

About Lilly

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers -- through medicines and information -- for some of the world's most urgent medical needs. Additional information about Lilly is available at www.lilly.com.

About BioMS Medical Corp.

BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, dirucotide, is for the treatment of multiple sclerosis. In December 2007, BioMS entered into a licensing and development agreement granting Eli Lilly and Company exclusive worldwide rights to dirucotide in exchange for an upfront payment, milestone payments and escalating royalties on sales. For further information please visit our website at www.biomsmedical.com.

This press release may contain forward-looking statements, which reflect the current expectation of Lilly and BioMS regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Ipsogen Reports Incorporation of the Genomic Grade in the 2009 St. Gallen International Consensus Meeting on the Primary Treatment of Early Breast Cancer
2. Jazz Pharmaceuticals and UCB Announce Second Phase III Study of Sodium Oxybate in Patients With Fibromyalgia Meets Primary Endpoints
3. MADIT-CRT Trial Meets Primary Endpoint
4. Micromets Blinatumomab Achieves Primary Endpoint in Phase 2 Study with Acute Lymphoblastic Leukemia Patients
5. Mayo Researchers Help Discover Genetic Cause for Primary Biliary Cirrhosis
6. Essentialis Meets Primary Endpoint in Phase 2b Trial of DCCR for Treatment of Hypertriglyceridemia and is Granted Extensive Patent Coverage in the US
7. Medarex Announces Primary Endpoint Achieved in MDX-1100 Anti-IP-10 Antibody Phase 2 Trial for Rheumatoid Arthritis
8. Antheras Varespladib Meets Primary Endpoint in Phase 2 FRANCIS Trial for the Treatment of Acute Coronary Syndrome
9. Phase 3 Trial of Nexavar in Chemotherapy-Naive Patients with Advanced Melanoma Does Not Meet Primary Endpoint
10. Schering-Ploughs Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study
11. VirtualScopics Quantitative Imaging Provides Primary Endpoint in Cartilage Repair Pivotal Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 2014  Alimera Sciences, Inc. (NASDAQ: ALIM ... research, development and commercialization of prescription ophthalmic pharmaceuticals, announced ... from Hercules Technology Growth Capital, Inc. (NYSE: ... final advance under the Loan and Security Agreement that ... , Alimera Sciences Limited, entered into with Hercules in ...
(Date:9/30/2014)... 30, 2014 A study using a relatively ... new look at the composition of carotid artery disease ... and treat the disease, a leading cause of stroke. ... Lexington between September 2010 and May 2012, was featured ... of the American College of Cardiology (JACC) Cardiovascular Interventions. ...
(Date:9/30/2014)... , Sept. 30, 2014 Valeant Pharmaceuticals International, ... today announced that the company,s Bridgewater, New ... the U.S. Food and Drug Administration (FDA) relating to ... with regards to Sculptra Aesthetic injectable, which was divested ... to the management of Valeant,s contract manufacturers (rather than ...
Breaking Medicine Technology:Alimera Sciences Receives $25 Million Advance from Hercules Technology Growth Capital 2New Imaging Tool May Allow Tailoring of Stroke Prevention to Each Patient 2Valeant Pharmaceuticals' Bridgewater Location Receives Warning Letter From FDA 2
(Date:9/30/2014)... has been awarded a three-year $1.7 million grant ... develop new imaging technologies and data analysis techniques ... networks of neurons in the brain interact to ... identify the precise interactions between millions of nerve ... and alterations in these interactions that may be ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 The ... option to help diabetics curb their sweet tooth, but ... Nature this September, suggests that zero-calorie sweeteners may ... 2 diabetes. , The Weizmann Institute of Science ... fed artificial sweeteners to mice, the mice developed glucose ...
(Date:9/30/2014)... Regenerative Medicine Solutions (RMS) is set to open ... RMS welcomes the launch of an entirely new facility, ... new treatment center for the Lung Institute. , ... Nashville, the hope is to bring awareness to those ... undiagnosed. With Nashville being a hub for medical technology, ...
(Date:9/30/2014)... Sept. 30, 2014 (HealthDay News) -- Medicare should cover ... high risk for the disease, a coalition of more ... coalition, which includes the Lung Cancer Alliance, the Society ... American Cancer Society and the American Society of Clinical ... to the U.S. Centers for Medicare & Medicaid Services ...
(Date:9/30/2014)... Chicago, IL (PRWEB) September 30, 2014 ... meet at the National Association of Health Advocacy Consultants ... of Healthcare Advocacyā€¯ (#NAHAC14) to be held October 30th ... Making its debut at NAHAC14: Standards and Best Practices ... advocacy grows into a profession, advocates have needed a ...
Breaking Medicine News(10 mins):Health News:UMD receives inaugural BRAIN Initiative Award 2Health News:Artificial Sweeteners May be Linked to Greater Diabetes Risk 2Health News:Regenerative Medicine Solutions Expanding 2Health News:Groups Call for Medicare Coverage of Lung Cancer Screening 2
... 2012 - VIB researcher Diether Lambrechts, associated with KU ... which patients will benefit more from treatment with bevacizumab ... step towards personalized medicine and patient-tailored use of this ... Leuven) said "in two large clinical studies with patients ...
... symptoms of heart disease already have heart damage, according to ... Heart Failure Congress 2012 , 19-22 May, in Belgrade, Serbia. ... Failure Association of the European Society of Cardiology., ... research has shown that obese adults have structural and functional ...
... Reinberg HealthDay Reporter , FRIDAY, May 18 (HealthDay News) ... Americans born between 1945 and 1965 -- the baby boom generation ... deadly disease occur in this age group, and most were infected ... the agency said. "CDC views this as an unrecognized health ...
... combination of three drugs used worldwide as the standard of ... of death or hospitalization, and should not be used together ... the surprising results of a rigorous independent study. The ... New England Journal of Medicine to coincide with a ...
... For more than three decades, researchers have warned of ... tobacco smoke (ETS), especially among children whose parents smoke. ... University of Arizona reports that those health risks persist ... individuals end up becoming smokers later in life. ...
... , SATURDAY, May 19 (HealthDay News) -- More than ... more than half of those victims are younger than age ... (May 20 to 26), the American Academy of Pediatrics is ... Postal Service to educate people about dog safety. They ...
Cached Medicine News:Health News:Biomarker predicts response to cancer treatment 2Health News:Obese adolescents have heart damage 2Health News:Test Baby Boomers for Hepatitis C, Says CDC 2Health News:First, do no harm: Study finds danger in standard treatment for a serious lung disease 2Health News:First, do no harm: Study finds danger in standard treatment for a serious lung disease 3Health News:Study says children exposed to tobacco smoke face long-term respiratory problems 2Health News:Study says children exposed to tobacco smoke face long-term respiratory problems 3Health News:Keeping Your Family Safe From Dog Bites 2
Research® Series 2100 Adjustable-volume Pipette, 0.5-10 µl, single-channel with adjustable-volume setting...
... Seven digital models cover the range from ... liquid fluently. Volume lock design prevents inadvertent ... the horizontal grip. Whole pipette is autoclavable ... ejector is all polypropylene. Suitable for one-handed ...
... The Finnpipette Digital offers improved ergonomics ... rounded handle, modified grippy finger rest ... operator comfort and efficiency. Finnpipette Digitals ... power-boosted gearing mechanism (pat. pend.) and ...
... 1991 Intersurgical Incorporated manufactures ... heat and moisture exchangers, ... products, hand-held nebulizers and ... accessories and connectors for ...
Medicine Products: